Antiemetic Efficacy of Ondansetron and Metoclopramide, Both Combined with Corticosteroid, in Malignant Lymphoma Patients Receiving Non-Cisplatin Chemotherapy

Comparison between Antiemetic Effects of Palonosetron and Granisetron on Chemotherapy-Induced Nausea and Vomiting in Japanese Patients Treated with R-CHOP

“…30) The use of dexamethasone and aprepitant also requires considerable attention because drug interactions may occur during R-CHOP therapy. 23,24) In the present study, the administration of palonosetron, not combined with dexamethasone and aprepitant, achieved a CR rate of over 90% during the delayed phase (Fig. 1), and the multivariate logistic regression analysis showed that palonosetron use was an independent significant factor improving the CR rate during the delayed phase, compared to granisetron use (Table 4).…”

“…To date, it has been reported that antiemetic regimens including the first-generation 5-HT 3 receptor antagonists ondansetron and granisetron were more effective for CINV control in patients with Hodgkin and non-Hodgkin lymphomas receiving MEC, compared to metoclopramide-based antiemetic regimens. 25,26) In addition, two single-arm studies conducted in Italy and Japan showed that a single dose of palonosetron was effective for achieving CR during overall, acute, and delayed CINV in more than 70% of patients with non-Hodgkin lymphoma. 16,18) In the present study, we compared antiemetic effects between palonosetron and granisetron, and found that the rate of CINV management with the use of palonosetron reached at least 70% during the overall study period and was non-inferior during the overall and acute phases and superior during the delayed phase, compared to granisetron use (Table 4).…”

Comparison between Antiemetic Effects of Palonosetron and Granisetron on Chemotherapy-Induced Nausea and Vomiting in Japanese Patients Treated with R-CHOP

“…30) The use of dexamethasone and aprepitant also requires considerable attention because drug interactions may occur during R-CHOP therapy. 23,24) In the present study, the administration of palonosetron, not combined with dexamethasone and aprepitant, achieved a CR rate of over 90% during the delayed phase (Fig. 1), and the multivariate logistic regression analysis showed that palonosetron use was an independent significant factor improving the CR rate during the delayed phase, compared to granisetron use (Table 4).…”

“…To date, it has been reported that antiemetic regimens including the first-generation 5-HT 3 receptor antagonists ondansetron and granisetron were more effective for CINV control in patients with Hodgkin and non-Hodgkin lymphomas receiving MEC, compared to metoclopramide-based antiemetic regimens. 25,26) In addition, two single-arm studies conducted in Italy and Japan showed that a single dose of palonosetron was effective for achieving CR during overall, acute, and delayed CINV in more than 70% of patients with non-Hodgkin lymphoma. 16,18) In the present study, we compared antiemetic effects between palonosetron and granisetron, and found that the rate of CINV management with the use of palonosetron reached at least 70% during the overall study period and was non-inferior during the overall and acute phases and superior during the delayed phase, compared to granisetron use (Table 4).…”

Antiemetic efficacy and safety of granisetron or palonosetron alone and in combination with a corticosteroid for ABVD therapy-induced nausea and vomiting

“…The ABVD therapy caused severe nausea and vomiting in about 50% of patients before the use of antiemetic agents is recommended [ 12 ], and thereby patients may refuse to complete its planned cycles [ 13 ]. To date, it has been reported that antiemetic regimens including the first-generation 5-HT 3 receptor antagonists, ondansetron and granisetron, were more effective for CINV control in patients with Hodgkin and non-Hodgkin lymphomas receiving moderately emetogenic chemotherapy (MEC), compared to metoclopramide-based antiemetic regimens [ 14 , 15 ]. In patients with HEC, to prevent CINV induced by ABVD therapy, triple antiemetic therapy (a 5-HT 3 receptor antagonist, dexamethasone, aprepitant) is recommended, although the data regarding the antiemetic effects of these medications are not entirely sufficient for patients with hematological malignancies.…”

Single-dose palonosetron for prevention of chemotherapy-induced nausea and vomiting in patients with aggressive non-Hodgkin's lymphoma receiving moderately emetogenic chemotherapy containing steroids: results of a phase II study from the Gruppo Italiano per lo Studio dei Linfomi (GISL)

“…Two previous studies have assessed the efficacy of first generation 5-HT 3 RA (ondansetron and granisetron) in malignant lymphoma patients undergoing CHOP like chemotherapy: one study [28] compared ondansetron and metoclopramide, while Numbenjapon et al compared granisetron (GRAN) and metoclopramide [29], both combined with corticosteroid (CS). Antiemetic prophylaxis in the OND study was: OND 8 mg/methylprednisolone 80 mg i.v.…”

“…The ultimate aim—neither nausea nor emesis—was reached in 77% of OND/CS-treated patients. The control of delayed nausea was obtained in 81% of patients [28]. Antiemetic prophylaxis in the Numbenjapon study [29] was GRAN 1 mg with 8 mg dexamethasone before chemotherapy and GRAN 1 mg daily on days 2–5.…”

Comparison between Antiemetic Effects of Palonosetron and Granisetron on Chemotherapy-Induced Nausea and Vomiting in Japanese Patients Treated with R-CHOP

“…30) The use of dexamethasone and aprepitant also requires considerable attention because drug interactions may occur during R-CHOP therapy. 23,24) In the present study, the administration of palonosetron, not combined with dexamethasone and aprepitant, achieved a CR rate of over 90% during the delayed phase (Fig. 1), and the multivariate logistic regression analysis showed that palonosetron use was an independent significant factor improving the CR rate during the delayed phase, compared to granisetron use (Table 4).…”

“…To date, it has been reported that antiemetic regimens including the first-generation 5-HT 3 receptor antagonists ondansetron and granisetron were more effective for CINV control in patients with Hodgkin and non-Hodgkin lymphomas receiving MEC, compared to metoclopramide-based antiemetic regimens. 25,26) In addition, two single-arm studies conducted in Italy and Japan showed that a single dose of palonosetron was effective for achieving CR during overall, acute, and delayed CINV in more than 70% of patients with non-Hodgkin lymphoma. 16,18) In the present study, we compared antiemetic effects between palonosetron and granisetron, and found that the rate of CINV management with the use of palonosetron reached at least 70% during the overall study period and was non-inferior during the overall and acute phases and superior during the delayed phase, compared to granisetron use (Table 4).…”

Antiemetic efficacy and safety of granisetron or palonosetron alone and in combination with a corticosteroid for ABVD therapy-induced nausea and vomiting

“…The ABVD therapy caused severe nausea and vomiting in about 50% of patients before the use of antiemetic agents is recommended [ 12 ], and thereby patients may refuse to complete its planned cycles [ 13 ]. To date, it has been reported that antiemetic regimens including the first-generation 5-HT 3 receptor antagonists, ondansetron and granisetron, were more effective for CINV control in patients with Hodgkin and non-Hodgkin lymphomas receiving moderately emetogenic chemotherapy (MEC), compared to metoclopramide-based antiemetic regimens [ 14 , 15 ]. In patients with HEC, to prevent CINV induced by ABVD therapy, triple antiemetic therapy (a 5-HT 3 receptor antagonist, dexamethasone, aprepitant) is recommended, although the data regarding the antiemetic effects of these medications are not entirely sufficient for patients with hematological malignancies.…”

Single-dose palonosetron for prevention of chemotherapy-induced nausea and vomiting in patients with aggressive non-Hodgkin's lymphoma receiving moderately emetogenic chemotherapy containing steroids: results of a phase II study from the Gruppo Italiano per lo Studio dei Linfomi (GISL)

“…Two previous studies have assessed the efficacy of first generation 5-HT 3 RA (ondansetron and granisetron) in malignant lymphoma patients undergoing CHOP like chemotherapy: one study [28] compared ondansetron and metoclopramide, while Numbenjapon et al compared granisetron (GRAN) and metoclopramide [29], both combined with corticosteroid (CS). Antiemetic prophylaxis in the OND study was: OND 8 mg/methylprednisolone 80 mg i.v.…”

“…The ultimate aim—neither nausea nor emesis—was reached in 77% of OND/CS-treated patients. The control of delayed nausea was obtained in 81% of patients [28]. Antiemetic prophylaxis in the Numbenjapon study [29] was GRAN 1 mg with 8 mg dexamethasone before chemotherapy and GRAN 1 mg daily on days 2–5.…”

Comparison between Antiemetic Effects of Palonosetron and Granisetron on Chemotherapy-Induced Nausea and Vomiting in Japanese Patients Treated with R-CHOP

“…30) The use of dexamethasone and aprepitant also requires considerable attention because drug interactions may occur during R-CHOP therapy. 23,24) In the present study, the administration of palonosetron, not combined with dexamethasone and aprepitant, achieved a CR rate of over 90% during the delayed phase (Fig. 1), and the multivariate logistic regression analysis showed that palonosetron use was an independent significant factor improving the CR rate during the delayed phase, compared to granisetron use (Table 4).…”

“…To date, it has been reported that antiemetic regimens including the first-generation 5-HT 3 receptor antagonists ondansetron and granisetron were more effective for CINV control in patients with Hodgkin and non-Hodgkin lymphomas receiving MEC, compared to metoclopramide-based antiemetic regimens. 25,26) In addition, two single-arm studies conducted in Italy and Japan showed that a single dose of palonosetron was effective for achieving CR during overall, acute, and delayed CINV in more than 70% of patients with non-Hodgkin lymphoma. 16,18) In the present study, we compared antiemetic effects between palonosetron and granisetron, and found that the rate of CINV management with the use of palonosetron reached at least 70% during the overall study period and was non-inferior during the overall and acute phases and superior during the delayed phase, compared to granisetron use (Table 4).…”

Antiemetic efficacy and safety of granisetron or palonosetron alone and in combination with a corticosteroid for ABVD therapy-induced nausea and vomiting

“…The ABVD therapy caused severe nausea and vomiting in about 50% of patients before the use of antiemetic agents is recommended [ 12 ], and thereby patients may refuse to complete its planned cycles [ 13 ]. To date, it has been reported that antiemetic regimens including the first-generation 5-HT 3 receptor antagonists, ondansetron and granisetron, were more effective for CINV control in patients with Hodgkin and non-Hodgkin lymphomas receiving moderately emetogenic chemotherapy (MEC), compared to metoclopramide-based antiemetic regimens [ 14 , 15 ]. In patients with HEC, to prevent CINV induced by ABVD therapy, triple antiemetic therapy (a 5-HT 3 receptor antagonist, dexamethasone, aprepitant) is recommended, although the data regarding the antiemetic effects of these medications are not entirely sufficient for patients with hematological malignancies.…”

Single-dose palonosetron for prevention of chemotherapy-induced nausea and vomiting in patients with aggressive non-Hodgkin's lymphoma receiving moderately emetogenic chemotherapy containing steroids: results of a phase II study from the Gruppo Italiano per lo Studio dei Linfomi (GISL)

“…Two previous studies have assessed the efficacy of first generation 5-HT 3 RA (ondansetron and granisetron) in malignant lymphoma patients undergoing CHOP like chemotherapy: one study [28] compared ondansetron and metoclopramide, while Numbenjapon et al compared granisetron (GRAN) and metoclopramide [29], both combined with corticosteroid (CS). Antiemetic prophylaxis in the OND study was: OND 8 mg/methylprednisolone 80 mg i.v.…”

“…The ultimate aim—neither nausea nor emesis—was reached in 77% of OND/CS-treated patients. The control of delayed nausea was obtained in 81% of patients [28]. Antiemetic prophylaxis in the Numbenjapon study [29] was GRAN 1 mg with 8 mg dexamethasone before chemotherapy and GRAN 1 mg daily on days 2–5.…”